Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.44 |
| ▸ | TSHR | P16473 | 8/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23985663 | 1.00 | CYP3A4 (0.44) | CYP3A4TSHRCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL30173657 | 0.84 | ALDH1A1 (0.47) | CYP3A4TSHRCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL23985814 | 0.84 | ALDH1A1 (0.47) | CYP3A4TSHRCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL23986002 | 0.83 | CYP3A4 (0.46) | CYP3A4TSHRCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL30173648 | 0.83 | CYP3A4 (0.46) | CYP3A4TSHRCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL30173645 | 0.83 | CYP3A4 (0.46) | CYP3A4TSHRCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL30209654 | 0.74 | NPC1 (0.34) | — | |
| SCHEMBL6163639 | 0.71 | PPARG (0.40) | TSHRCYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL22698689 | 0.71 | ATM (0.56) | CYP3A4TSHRCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5162450 | 0.71 | ALDH1A1 (0.47) | CYP3A4TSHRCYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143193-B1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-22 | — | — | EP | disclosed |
| US-12559496-B2 | Imidazopyrimidines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-24 | — | — | US | disclosed |
| CN-115867348-B | Imidazopyrimidines as IL-17 modulators | 詹森药业有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20230242537-A1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA N.V. (BE) | 2023-08-03 | — | — | US | disclosed |
| CN-115867348-A | Imidazopyrimidines as IL-17 modulators | 詹森药业有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4143193-A1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | JANSSEN Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242537-A1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL2 | CYP3A4 994/4885TSHR 1013/4885CYP2C9 2012/4885 |
| US-12559496-B2 | Imidazopyrimidines as modulators of IL-17 | IL17A, IL2, IL23R | CYP3A4 530/4885TSHR 846/4885CYP2C9 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.